Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis

NCT04130997 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT04130997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04130997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 18, 2019
Completion date
May 31, 2032
Enrollment
1,100 (estimated)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis (rms)